| Objectives:To study how microwave ablation treatment changes the concentration of serum idl in patients with advanced non-small cell lung cancer, and the clinical efficacy when combined with systemic chemotherapy.Methods:20 cases of healthy human serum were chosen as blank control,21 patients as test and 19 patients as control. Test group underwent microwave ablation treatment after 8 to 12 days of chemotherapy, and followed up by chemotherapy, a total of 4 to 6 cycles of chemotherapy. Control group simply underwent 4 to 6 cycles of chemotherapy. Patients were given different schemes according to their pathological classification, GP programme for squamous carcinoma patients (Gem 1.0 g/m2 ivdrip dl,8; DDP 25 mg/m2 ivdrip dl-3, day 1 cycle) and PC programme for non squamous carcinoma (Pem 0.5 g/m2 ivdrip dl; DDP 25 mg/m2 dl-3; 21 days 1 cycle). RECIST were used to evaluate therapeutic response every 2 cycles of chemotherapy. Patients with progressive disease were treated with Docetaxel (Doc 75 mg/m2 ivdrip dl,21 days 1 cycle), The rest of the patients maintain the original chemotherapy regimens. The patient peripheral blood samples were collected at 3 time points, before microwave ablation, after microwave ablation and after the whole treatment process. Then, the serum concentration of id-1 protein were measured by ELISA kit and compared among different groups by statistical methods. Observe the patient efficient rate (RR), disease control rates (DCR), progression-free survival (PFS) and overall survival (OS) of test group and control group, respectively.Results:After a double-antibody sandwich ELISA assay, serum idl concentration was found to be significantly lower in healthy people than in patients with advanced NSCLC (P<0.05). Serum idl level of test group significantly increased 7 days after microwave ablation than before (P<0.05). After 4 to 6 cycles of chemotherapy, the serum idl levels showed no significant difference between test group and control group (P>0.05), and significantly decreased than before chemotherapy (P<0.05).Term effect:The patients in both observation group and control group did not reach complete remission(CR). In observation group, there were 8 cases of partial remission (PR), 10 cases of stable disease (SD) and 3 cased of progressive disease (PD). The efficiency rate (RR) was 38.1%(8/21) and disease control rate was 85.7%(18/21). In control group, there were 5 cases of partial remission (PR),6 cases of stable disease (SD),8 cases of progressive disease (PD). the efficiency rate (RR) was 26.3%(5/19) and disease control rate was 57.8% (11/19). The efficiency rate (RR) showed no significant difference between observation group and control group (χ2=0.63, P>0.05), while disease control rate (DCR) showed significant difference (χ2=3.87, P<0.05). the progressive free survival (PFS) were 7.1 months and 4.9 months for test group and control group, respectively. The 1-year survival rate were 47.6% and 31.6%, respectively, with no significant difference (P>0.05).Conclusion:1.Microwave ablation treatment of advanced NSCLC was minimally invasive, efficient, safe and had fewer side effects.2.The serum idl concentration in non-small cell lung cancer patients was significantly higher than in healthy volunteers.3. For patients with advanced NSCLC, the serum idl protein concentration was significantly higher after microwave ablation treatment than pre-treatment. Microwave ablation with combined chemotherapy can effectively decrease the patient serum idl protein concentration. After 4-6 cycles of chemotherapy, the concentration was lower than before chemotherapy.4. Microwave ablation with combined systemic chemotherapy can prolong disease progression period and increase survival rates. |
PDF Full Text Request